A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
- Status
- RECRUITING
- Phase
- PHASE2
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
- Status
- ENROLLING_BY_INVITATION
- Phase
- NA
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
- Status
- RECRUITING
- Phase
- PHASE2